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ABSTRACT OF THESIS

GLUTAMATE DYSREGULATION AND HIPPOCAMPAL DYSFUNCTION IN
EPILEPTOGENESIS

Epileptogenesis is the complex process of the brain developing epileptic
acitivity. Due to the role of glutamate and the hippocampus in synaptic plasticity
a dysregulation in glutamate neurotransmission and hippocampal dysfunction are
implicated in the process of epileptogenesis. However, the exact causal factors
that promote epileptogenesis are unknown.
We study presynaptic proteins that regulate glutamate neurotransmission
and their role in epileptogenesis. The presynaptic protein, tomosyn, is believed
to be a negative regulator of glutamate neurotransmission; however, no one has
studied the effects of this protein on glutamate transmission in vivo.
Furthermore, evidence suggests that mice lacking tomosyn have a kindling
phenotype. Thus, in vivo glutamate recordings in mice lacking tomosyn have the
potential to elucidate the exact role of tomosyn in glutamate neurotransmission
and its potential relationship to epileptogenesis.
Here we used biosensors to measure glutamate in the dentate gyrus
(DG), CA3, and CA1 of the hippocampus in tomosyn wild-type (Tom+/+),
heterozygous (Tom+/-), and knock out (Tom-/-) mice. We found that, in the DG,
that glutamate release increases as tomosyn expression decreases across
genotype. This suggests that tomosyn dysregulation in the DG leads to an
increase in glutamate release, which may explain why these mice have an
epileptogenic phenotype.
KEYWORDS: Electrochemistry, Epileptogenesis, Glutamate, Hippocampus,
Tomosyn
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Chapter One: Introduction

L-Glutamate is the neurotransmitter necessary for proper cognitive
functioning and memory formation (Platt, 2007). However, dysregulation of
glutamate is thought to underlie several neurological and psychiatric diseases
(Meldrum, 2000). Specifically, hippocampal glutamate dysregulation seems to
be a factor in several diseases (Rupsingh et al., 2011; Billa et al., 2010; Scheyer,
1998).
The hippocampus is the brain area most associated with learning and
memory (Deng et al., 2010). In the hippocampus glutamate transmitter and
receptor dynamics, specifically through long-term potentiation (LTP) and longterm depression (LTD), are considered to be the underlying mechanisms that are
thought to promote memory formation and synaptic plasticity (Lüscher &
Malenka, 2012). However, aberrant synaptic plasticity can occur which can
promote diseases such as epilepsy (Scheyer, 1998).
Epileptogenesis is a complex process involving molecular, cellular, and
neural network changes that result in dysregulated synaptic activity (Bertram,
2007). Furthermore, some have suggested that the process of epileptogenesis is
similar to the molecular changes that occur in the formation of normal long-term
memories (Hannesson & Corcoran, 2000). Since glutamate neurotransmission
and the hippocampus are essential in memory formation and synaptic plasticity
dysfunctions of these systems may promote epileptogenesis (Morris et al., 2000;
Wasterlain et al., 2000). We have focused on studying glutamate dynamics in
the hippocampus by specifically examining changes in presynaptic proteins that
regulate glutamate release and their effect on epileptogenesis (Matveeva et al.,
2011a; Matveeva et al., 2011b; Matveeva et al., 2008; Matveeva et al., 2007;
Matveeva et al., 2003). To this end, we have used the kindling model of
epileptogenesis to assess these molecular and neurotransmitter changes.
Previously our group has shown that kindling in rats promotes
asymmetrical accumulation of one of the major components of the secretory
machinery, the 7 svedberg SNAP (soluble N-ethylmaleimide sensitive factor
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[NSF] attachment protein) receptor (7S SNARE) complex (7SC) (Matveeva et al.,
2008; Matveeva et al., 2007; Matveeva et al., 2003). Minimally, this complex is a
heterotrimer composed of the membrane-bound t-SNAREs, syntaxin and
synaptosomal-associated protein 25 (SNAP-25), and the vesicle-bound vSNARE, synaptobrevin/vesicle-associated membrane protein 2 (VAMP2) (Jahn &
Scheller, 2006). Furthermore, we have shown that synaptic vesicle protein (SV2)
and NSF, regulators of the 7SC, show long-term alterations in the ipsilateral
hippocampus in the CA1 and DG following kindling (Matveeva et al., 2008).
Also, roughly a 50% knock down of VAMP2 in mice created a kindling resistant
phenotype (requiring more current and stimulations to reach a fully kindled state)
and caused a decrease in KCl-evoked glutamate release in the DG and CA3 of
the hippocampal formation (Matveeva et al., 2011b). These results suggest that
proteins involved in glutamate release and regulation may have a role in
epileptogenesis.
Tomosyn is a presynaptic protein that negatively regulates glutamate
release (Sakisaka et al., 2008). Tomosyn is thought to inhibit neurotransmitter
release primarily by sequestering syntaxin and thus inhibiting 7SC formation
(Asher et al., 2009) (Figure 1.1). Furthermore, tomosyn is preferentially
expressed in the hippocampus mainly in glutamatergic synapses (Brakak et al.,
2010). Evidence from hippocampal mossy fibers has shown that neurons lacking
tomosyn have an increased probability of neurotransmitter release as measured
electrophysiologically looking at excitatory post-synaptic potentials (EPSPs)
(Sakisaka et al., 2008). Building on those results, we have shown that tomosyn
knockout mice exhibit a kindling phenotype requiring fewer stimulations to reach
a Racine stage 5 seizure (Figure 1.2). Taken together, the above evidence
suggests that tomosyn dysregulation may cause increased glutamate release
and promote epileptogenesis.
No group has yet measured glutamate release in vivo in tomosyn
knockout mice to assess whether changes in tomosyn expression actually affect
glutamate release in an intact biological system. Here we measured glutamate in
subregions of the hippocampus (dentate gyrus [DG], CA3, and CA1) using
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biosensors selective for glutamate in tomosyn wild type (Tom

+/+

), tomosyn

heterozygous (Tom +/-), and tomosyn knockout (Tom-/-) mice. Using biosensors
with a high temporal and spatial resolution this thesis presents data on glutamate
measurements from mice lacking tomosyn. In chapter one, the glutamate
system, hippocampus, and epileptogenesis are discussed, in chapter two the
methodology used is discussed, and in chapter three the data are presented and
discussed.
Glutamate System Dynamics
Glutamate, like most neurotransmitters, maintains homeostatic tone by
tightly regulating release and uptake as well as the receptors and transporters
associated with these processes. Here the specifics of the glutamate system are
discussed starting with release then moving on to discuss transporters and
receptors and how these dynamics are related to epileptogenesis.
Synthesis & Release
Glutamine and α-ketoglutarate are the two precursors in glutamate
synthesis (Tapiero et al., 2002). Glutamine and α-ketoglutarate are taken up by
neurons in a Na+ dependent fashion; glutamate is synthesized from glutamine via
the enzyme glutaminase and from a-ketoglutarate via a transamination reaction
(Anderson & Swanson, 2000; Daikhin & Yudkoff, 2000). Glutamate is then taken
up by vesicular glutamate transporters (VGLUTs) in an energy dependent
fashion and packaged into vesicles (Fonnum et al., 1998) (Figure 1.3). After
packaging, glutamate is released in a Ca2+ dependent fashion into the synaptic
cleft (Meldrum, 2000; Turner, 1998). Once released, glutamate either: (a) binds
to pre and post-synaptic glutamate receptors, (b) is actively taken up by glia and
synthesized back into glutamine via glutamine synthase, (c) actively transported
by presynaptic neurons and repackaged, or (d) diffuses away from the synapse
(Anderson & Swanson, 2000; Attwell, 2000; Daikhin & Yudkoff, 2000).
Transporters
Five glutamate transporters have been found in the mammalian central
nervous system (CNS) (Meldrum, 2000). Of these five, two are expressed in glial
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cells and are responsible for 90% of glutamate uptake (excitatory amino acid
transporter 1 [EAAT1; referred to as GLAST1 in rats] and EAAT2 [referred to as
GLT1 in rats]) and three post-synaptically in neurons (EAAT3 [referred to as
EAAC1 in rats; cortical neurons], EAAT4 [cerebellar Purkinje neurons], EAAT 5
[retina neurons]) (Iverson et al., 2009; Danbolt et al., 1998; Seal & Amara, 1999)
(Figure 1.4). EAAT1-5 all transport glutamate in a Na+ dependent fashion
(Kataoka et al., 1997). Interestingly, EAAT3-5 seem to be linked to Cl- channels
as well as being sodium dependent; when glutamate binds to the postsynaptic
transporters Cl- channels also open and decreases synaptic activity via
hyperpolarization (Levy et al., 1998). This is thought to be a negative-feedback
system for glutamate release (Levy et al., 1998).
These transporters are enantioselective (D-Aspartate [D-Asp], L-Aspartate
[L-Asp], and L-glutamate are all substrates whereas D-glutamate is not) with
affinities that range from Km values from 10-100 μM with the exception of EAAT4,
which has a Km value of approximately 2 μM (note this affinity is much higher
than that seen by VGLUTs with Km values approximately equal to 1 mM) (Iverson
et al., 2009; Meldrum, 2000; Danbolt et al., 1998). Once glutamate is taken up
by glia and/or neurons it is metabolized and recycled (see ‘Synthesis & Release’
section). Now that glutamate synthesis, release, and transporters have been
discussed, next the receptors to which neuronally-released glutamate can bind to
will be reviewed.
Glutamate Ionotropic Receptors
There are three classes of ionotropic receptors: N-methyl-D-aspartate
(NMDA), α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), and
kainic acid (Iverson et al., 2009; Meldrum, 2000). Each was identified and
defined first by their pharmacology and later by their molecular biology (Meldrum,
2000; Tzschentke, 2002). Here all three are discussed in detail because of their
suggested dysfunction in epileptogenesis and epilepsy (Higuchi et al., 2000;
Musshoff et al., 2000).
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The NMDA Receptor
The NMDA receptors (NMDARs) are ligand and voltage-gated, postsynaptic ion channels that are permeable to Na+, K+, and Ca2+ (Kew & Kemp,
2005; Madden, 2002) (Figure 1.4). The receptor has several modulatory binding
sites: (a) glutamate binding site that binds not only transmitter but related
agonists as well (within this area it has been suggested that one part of this site
has a preference for agonist while the other a preference for antagonist), (b) a
glycine binding site; glycine is a necessary cofactor for glutamate activation of
the NMDAR however recent evidence suggests that this site may bind D-serine,
which is not at saturating levels in the brain like glycine, (c) a site inside the
receptor that binds phencyclidine (PCP) and other noncompetitive antagonists,
(d) a voltage-dependent Mg2+ binding site inside the receptor, (e) an inhibitory
cation site located near the mouth of the channel that binds Zn 2+ causing a
voltage-independent block, and (f) a polyamine regulatory site whose activation
by spermine and spermidine can enhance NMDAR activity at lower
concentrations but inhibit the receptor at higher concentrations (Iverson et al.,
2009; Mayer, 2005; Kew et al., 2000; Madden, 2002; Anson et al., 1998).
The above regulatory sites are found on the different complexes of the
NMDARs (Kew et al., 2000; Anson et al., 1998). The NMDARs are primarily
composed of two families of subunits: NR1 subunit (represented by one gene)
and the NR2 subunit (represented by four genes [NR2A-NR2D]) (Kew & Kemp,
2005; Meldurm, 2000). There is also some evidence that NR3A and NR3B
subunits also exist, and while they seem to decrease the NMDARs’ Ca2+
permeability, the physiological significance of these subunits are not well
understood (Matsuda et al., 2002; Sasaki et al., 2002; Nishi et al., 2001). There
is some evidence that NR1 homomeric NMDARs can exist although they do not
seem to pass ions very readily and their ion conductance increases
approximately 100-fold when coexpressed with NR2 subunits (Nestler et al.,
2009). Recent evidence suggests that this increase in conductance is due to the
glutamate binding site being located on the NR2 subunit; thus, it is now believed
that most functional NMDARs are composed of heteromeric complexes of NR1
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and NR2 subunits (Kew & Kemp, 2005). All of the regulatory sites found on
these difference subunits work together to modulate the function of the receptor.
The various regulatory sites found on the subunits on the NMDAR has
prompted the appellation ‘coincident receptor’ due its necessity for two
coagonists (glutamate and glycine/D-serine) as well as the voltage-dependent
removal of the Mg2+ ion for NMDAR function (Nestler et al., 2009; Madden, 2002;
Kew et al., 2000; Anson et al., 1998). Along with this, the NMDARs’ permeability
to Ca2+ has drawn much attention due to the many modulatory roles Ca2+
performs inside neurons (Lüscher & Malenka, 2012). Thus, the NMDARs role as
a ‘coincident detector’ as well as its permeability to Ca2+ seems to be the driving
force for NMDARs in synaptic plasticity, perhaps even for the aberrant synaptic
plasticity that may be involved in epileptogenesis (Morris et al., 2000; Wasterlain
et al., 2000).
The AMPA Receptor
AMPA receptors (AMPARs) are ligand-gated, post-synaptic ion channels
with two glutamate binding sites that, when bound to glutamate, allow the influx
of Na+ and Ca2+ (subtype specific; see below) and the efflux of K+ (Dingledine et
al., 1999) (Figure 1.4). AMPARs have a lower affinity for glutamate compared to
NMDA receptors; however, AMPA receptors do have faster kinetics and are
responsible for the quicker initial component of EPSPs (Dingledine et al., 1999).
AMPARs exist as heterotetramers consisting of various combinations of
subunits termed GluR1-4 (Rosenmund et al., 1998). The majority of AMPARs
contain GluR2 subunits and can only pass Na+ and K+ ions; however, some
AMPARs lack the GluR2 subunit and are permeable to Ca2+ (Bowie & Mayer,
1995). GluR2 lacking receptors are able to pass Ca2+ ions due to a difference in
the glutamine/arginine site (Q/R site) on the GluR2 subunit; the GluR1,3,4
subunits contain a glutamine at the Q/R site whereas on the GluR2 subunit this
site contains an arginine which repels the Ca2+ ions thus preventing them from
entering neurons (Seeburg & Hartner, 2003; Dingledine et al., 1999). AMPARs
can also exist in different splice variants termed Flip and Flop that influence the
rate of desensitization and the efficacy of certain allosteric modulators (Kew &

6

Kemp, 2005). Different cells in various brain regions can also express different
subtypes and splice variants of AMPARs.
Evidence suggests that, in the hippocampus, GluR2 lacking AMPARs are
predominantly found on inhibitory interneurons whereas GluR2 containing
AMPARs are found predominantly on pyramidal neurons (Mahanty & Sah, 1998).
Further, there is evidence that Ca2+ entering through GluR2 lacking receptors
may prompt migration of GluR2 containing receptors to the cell membrane (Liu &
Cull-Candy, 2002). Taken together, this evidence suggests not only another
level of synaptic plasticity but also a potential glutamatergic/AMPAR selfregulatory mechanism. Further, differential expression of GluR1-4 containing
AMPARs are seen in epileptogenesis suggesting that the expression of these
receptors changes in epilepsy, which may initiate and/or promote this disease
(Higuchi et al., 2000). A similar trend is seen with kainate receptors.
Kainate Receptor
The kainate receptor is a ligand-gated ion channel located both pre and
post-synaptically (Lerma, 2003). When activated by glutamate, presynaptic
kainate receptors can facilitate or inhibit neurotransmission; post-synaptically
kainate receptor stimulation causes slow EPSPs (Cossart et al., 2002; Lauri et
al., 2001; Kidd & Isaac, 1999). The receptor contains two glutamate binding sites
that must both be bound by glutamate in order for the ion channel to open and
allow Na+ and Ca2+ (depending on subunit composition) influx and K+ efflux
(Pinaheiro & Mulle, 2006; Sommer et al., 1991) (Figure 1.4).
Kainate receptors are tetrameric complexes of GluR5-7 and KA1-2
subunits (Bleakman et al., 2002). Homotetrameric complexes of KA1-2 subunits
do not create functional receptors; however, homotetrameric complexes of
GluR5-7 subunits do create functional receptors (Alt et al., 2004; Gallyas et al.,
2003; Bleakman et al., 2002). Further, heterotetrameric complexes of GluR5-7
and KA1-2 frequently occur and create functional kainate receptors as well
(Bleakman et al., 2002).
GluR5-7 subunits can be alternately spliced to induce greater receptor
variation and GluR5 and GluR6 subunits can be edited at the Q/R site to vary the
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receptors permeability to Ca2+ (Dingledine et al., 1999; Schiffer et al., 1997; Herb
et al., 1996). Kainate receptors are differentially expressed in the brain
(Contractor et al., 2000). For example, there is evidence that GluR5 expressing
kainate receptors are in high concentration in the temporal lobe (Rogawski et al.,
2003). Further, theses receptors can even be differentially expressed in different
subregions of a given brain area such as in the hippocampus (Contractor et al.,
2000). KA1 and KA2 containing receptors are found in DG mossy fibers where
KA2 containing receptors are predominately post-synaptic; KA2-GluR5
heteromeric receptors seem to be expressed post-synaptically in pyramidal
neurons in the CA3 (Jaskolski et al., 2005). Thus, with varying splice forms and
differential CNS expression these receptors allow further complexity and modes
for synaptic plasticity. Further, their dysfunction has been implicated in
epileptogenesis (Putkonen et al., 2011). Ionotropic receptors are not the only
receptors important in glutamate homeostasis nor are they the only ones
implicated in epileptogenesis. Metabotropic receptors are also an important
aspect of the glutamate system and their proper functioning are essential to
glutamate homeostasis as well.
Metabotropic Glutamate Receptors
Metabotropic glutamate receptors (mGluRs) are seven trans-membrane
spanning G-protein coupled receptors that signal to various second messenger
systems and that, when activated by glutamate, have a slower more modulatory
role than ionotropic receptors (Pin & Acher, 2002; Kunishima et al., 2000). There
are currently eight subtypes of mGluRs separated into three groups according to
their sequence homology, second messenger systems, and pharmacology
(Kunishima et al., 2000; Dingledine et al., 1999). It is thought that a malfunction
of these receptors may promote epileptogenesis by inducing excitotoxicity not
only by binding to glutamate but also by not appropriately modulating other
neuronal receptors (Sayin & Rutecki, 2003; Meldrum et al., 1999). Thus, there
importance in normal and pathological functions is discussed here.
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Group I mGluRs
This group of metabotropic receptors contains mGluR1 and mGluR5
(Niswender & Conn, 2010). These receptors are found post-synaptically and
they both have excitatory actions on neurons (Niswender & Conn, 2010;
Coutinho & Knopfel, 2002) (Figure 1.4). When bound by glutamate, mGluR1,5s
work through second messenger systems via Gq proteins which stimulate
phospholipase C (PLPC) to create/release inositol 1,4,5-triphosphate (IP3) and
diacylglycerol (DAG), both which work to release Ca2+ from intracellular stores to
several effector proteins (Hermans & Challiss, 2001). DAG also stimulates
protein kinase C (PKC) which can then stimulate several different downstream
effectors as well (Hermans & Challiss, 2001). Activation of these receptors may
also promote synaptic plasticity via LTP and LTD (Bellone et al., 2008; Kullmann
& Lamsa, 2008). mGluR1,5s can also undergo alternate splicing thus increasing
receptor variation and their effect on cellular function (Joly et al., 1995; Pin &
Duvoisin, 1995).
Evidence suggests that mGluR1,5 may both promote epileptogenesis;
however, mGluR5 seems to be more important in inducing this disease process
(Bianchi et al., 2012). It has been shown that this epileptogenic effect is
independent of ionotropic receptors and that the activation of these mGluR group
I receptors causes long lasting enhancement in the responsiveness of
hippocampal networks (Merlin, 1999). One such long lasting change seems to
be the development of a voltage-dependent cationic current that promotes rapid
neuronal firing and prolonged action potentials in the hippocampus (Chuang et
al., 2005; Young et al., 2004). Thus, the malfunction of the mGluR group I
receptors seems to have a role in epileptogenesis.
Group II mGluRs
Group II mGluRs comprise mGluR2 and mGluR3 (Niswender & Conn,
2010). These receptors are found both pre and post-synaptically and, when
bound by glutamate, generally have an inhibitory effect on excitatory, inhibitory,
and modulatory neurons (Niswender & Conn, 2010; Tamaru et al., 2001) (Figure
1.4). mGluRs2,3 have primarily a pre-terminal localization on presynaptic cells

9

and mGluR3 may also be present on glial cells (Ferraguti & Shigemoto, 2006;
Tamaru et al., 2001). The presynaptic mGluRs2,3 can be activated by excess
synaptic glutamate or glutamate release from astrocytes via the cysteineglutamate transporter (Kalivas, 2009).
The receptors generally work through Gi/o proteins which inhibit adenylyl
cyclase (AC) and cAMP formation and releases Gβγ which affects downstream
signaling proteins as well as directly activates K+ channels and inhibits voltagesensitive Ca2+ channels (Pin & Duvoisin, 1995; Tanabe et al., 1992). The
diversity of the mGluRs2,3 and their effects on neurons can also be increased by
alternate splicing (Sartorius et al., 2006). There is evidence to suggest that
dysfunctional mGluRs2,3 may be important in the process of epileptogenesis.
Kew et al. (2001) found that agonists binding at these receptors decreases
EPSPs in hippocampal neurons suggesting that a decrease in receptor number
or a malfunction resulting in reduced agonist binding may increase EPSPs in
hippocampal neurons. It has been shown that mGluRs2,3 activation in the
hippocampus decreases glutamate release and that stimulation of mGluR3 on
glial cells may increase glutamate uptake (Mateo & Porter, 2007; Zhao et al.,
2006). Further, activation of these receptors also increased the seizure threshold
in kindled rodents (Attwell et al., 1998). Thus, these receptors work to decrease
neuronal excitation and may suppress epileptogenesis however any malfunction
in these receptors may promote epileptogenesis.
Group III mGluRs
The group III receptors consist of mGluRs4,7,8 and are primarily located
presynaptically in the active zone of neurons (Niswender & Conn, 2010) (Figure
1.4). When bound by glutamate these receptors generally inhibit
neurotransmitter release and due to location of these receptors in the active zone
of neurons they have the ability to regulate cells via negative-feedback
mechanisms (Niswender & Conn, 2010). Furthermore, mGluR7 has a lower
affinity for glutamate compared to mGluRs4,8, thus it takes robust glutamate
release to activate mGluR7 compared to others in this group (Schoepp et al.,
1999).
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mGluRs 4,7,8 are coupled to Gi/o proteins which inhibit AC and cAMP
formation and releases Gβγ which affects downstream signaling proteins (Pin &
Duvoisin, 1995). mGluRs7,8 can be alternately spliced but mGluR4 cannot be,
thus more diversity is seen in mGluRs7,8 in contrast to mGluR4 receptors
(Malherbe et al., 1999; Corti et al., 1998). Note that mGluR6 also fits into this
group however this receptor subtype is only located on bipolar cells in the retina
and seems to have no role in epileptogenesis in the hippocampus (Nicoletti et al.,
2011).
Group III mGluRs generally seem to be antiepileptic: an increase in
mGluR4 is seen in patients with a history of temporal lobe epilepsy whereas no
such increase is seen in controls. This would suggest that a compensatory
increase in mGLuR4 is seen in those undergoing epileptogenesis (Lie et al.,
2000). Further, there is evidence that mGluR group III agonists reduce seizures
in rodents (Tizzano et al., 1995). Thus, the role of these receptors in
epileptogenesis is similar to the group II mGluRs.
Many disruptions in the glutamate system may occur in epileptogenesis
ranging from issues with glutamate release to receptor malfunctions. However,
no single malfunction alone seems to drive epileptogenesis; instead it seems that
a synergistic effect drives a vast network change in the hippocampus that
promotes this disease. Thus, the hippocampus as a network and the changes
that it incurs must be discussed to fully attempt to understand epileptogenesis.
The Hippocampus: A Focus on Structure & Function
The hippocampus is a region of the brain that is implicated in many
important processes such as spatial learning and memory. Dysfunction of the
hippocampus is thought to cause several disease states including
epileptogenesis. Here the structure and function of the trisynaptic pathway of the
hippocampus are discussed specifically in relation to the glutamate system and
epileptogenesis.
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The Trisynaptic Pathway: Structure & Connectivity
There are two major glutamatergic systems that project through the
hippocampus: (1) the unidirectional trisynaptic pathway, (2) the entorhinal cortex
direct projections to specific hippocampal subfields (Tamminga et al., 2012). The
trisynaptic pathways consists of the entorhinal cortex (EC), the DG, CA3, and
CA1 (Amaral & Witter, 1989). The hippocampus in general, and specifically the
trisynaptic pathway, is an area with a high number of glutamatergic neurons and
glutamate projections (Amaral & Witter, 1989).
The trisynaptic path starts in the EC and the projections travel through the
perforant path (through layers II/III) and synapse on the proximal dendrites of the
DG granule cell neurons. Mossy fiber projections then carry signals to synapse
on the proximal dendrites of CA3 pyramidal neurons. Signals then travel through
the Schaffer collaterals bilaterally to dendrites in the CA1. CA1 pyramidal
neurons then project to the subiculum which projects back to the EC, layer IV
(Tamminga et al., 2012) (Figure 1.5).
The mossy fiber connections from the DG to the CA3 are of particular
interest in the trisynaptic loop; one mossy fiber axon from the granule cell layer in
the DG can create a glutamatergic synapse with 8-15 excitatory pyramidal
neurons and 18-35 GABAergic interneurons all with Ca2+ dependent release
dynamics (Pelkey & McBain, 2008; Lawrence & McBain, 2003; Toth et al., 2000).
Further, each mossy fiber connection on interneurons has a distinct anatomical,
electrophysiological, and molecular profile suggesting that this system is tightly
controlled and regulated (Tamminga et al., 2012).
Results from measuring EPSPs in vitro also suggest that DG basal activity
has a feed-forward inhibitory function on the CA3 that seems to occur through
two distinct mechanisms in mossy fiber-interneuron connections from the DG to
the CA3: (1) through post-synaptic GluR2-lacking AMPA receptors, (2) through
presynaptic mGluR7 metabotropic receptors (Lawrence & McBain, 2003). Both
of these mechanisms work to inhibit and stabilize neuronal firing in the CA3
either through the firing of GABAergic interneurons (mechanism [1]) or through
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feedback inhibition of glutamate release from mossy fibers onto GABAergic
interneurons (mechanism [2]) (Lawrence & McBain, 2003).
Interestingly, when stimulating the DG granule neurons with high
frequency stimulation, the nature of mossy fiber signaling changes in the CA3
such that LTD occurs at the mossy fiber-interneuron synapse thus diminishing
inhibition while also causing LTP to occur at the mossy fiber-pyramidal synapse;
both result in excitation of CA3 neurons (Lawrence & McBain, 2003). The direct
projections of the EC are to the CA3 and CA1 subfields of the hippocampus
(Tamminga et al., 2012). These connections seem to be functionally important
due to the fact that they might regulate CA3 and CA1 output along with neurons
in the trisynaptic loop (Andersen et al., 2007; Witter, 1993). Taken together
these various connections suggest that the trisynaptic loop is highly regulated
and can work to perform very complex and specific tasks. Further, it also
suggests that if this regulation is lost complex pathological changes such as what
are seen in epileptogenesis could occur.
Although, many of these studies are conducted in rats, these data should
be considered highly relevant to humans since the hippocampal formation is a
conserved brain region in mammals (Andersen et al., 2007).
The Hippocampus: Function
The most documented function of the hippocampus is as a hub for
synaptic plasticity, spatial memory, and emotional memory (Squire, 1992;
Scoville & Milner, 1957). Evidence for this comes not only from the fact that
glutamate is the primary neurotransmitter released from neurons in this area but
also that LTP and LTD readily occur here (Lawrence & McBain, 2003; Amaral &
Witter, 1989). In addition, there is now evidence that neurons readily regenerate
in the DG of the hippocampus further showing the robust synaptic changes that
can happen in this brain area (Zhao et al., 2008).
All types of memory formation may not occur here; for example there is
evidence that the hippocampus may be more prone to consolidate spatial,
context, episodic, and certain types of emotional memories as opposed to other
types of memories such as declarative (Bonne et al., 2008; Stote & Fanselow,
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2004; Kim & Fanselow, 1992). There is recent evidence that different regions of
the hippocampus store different types of memories; for example the dorsal
hippocampus may store spatial memories whereas the ventral hippocampus may
store primarily emotional memories (Fanselow & Dong, 2010). The hippocampus
is also the brain region that works to first learn new information (Battaglia et al.,
2011). Because of the vast degree of synaptic plasticity that can occur in this
area, it is not surprising that there is evidence of pathological synaptic plasticity,
likely due to glutamate dysregulation, which can promote disease states such as
epileptogenesis (Leonard & Kirby, 2002;Tzschentke, 2002; Chapman, 2000).
Epileptogenesis: The Role of Glutamate & The Hippocampus
Epilepsy is a debilitating disease characterized by chronic seizures.
Epileptogenesis is the process of the brain becoming epileptic. The exact
mechanism that drives epileptogenesis and epilepsy is unknown however there
is evidence to suggest that epileptogenesis may be due to glutamate
dysregulation specifically in the hippocampus. Epileptogenesis and the role of
glutamate and the hippocampus in this process are discussed here.
What is Epileptogenesis?
The generally accepted definition of epileptogenesis is the process of the
brain acquiring an initial insult and secondarily undergoing a series of epileptic
events until the first observable seizure occurs (Giblin & Blumenfeld, 2010;
Rakhade & Jensen, 2009; Walker et al., 2002). However, there is a debate on
the exact definition of epileptogenesis specifically in terms of when
epileptogenesis starts and at what time it evolves to epilepsy (Sloviter &
Bumanglag, 2012).
Dudek & Staley (2011) and Pitkänen et al. (2011) expand the definition of
epileptogenesis to incorporate the never-ending evolution of changes in seizure
frequency and the development of a refractory state. On the other hand, Sloviter
& Bumanglag (2012) have defined epileptogenesis as the finite process that
leads to the first of a series of spontaneous and recurring epileptiform events that
disrupt behavior or thought processes in anyway, whether they are clinically
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relevant or not. Furthermore, Sloviter & Bumanglag (2012) have proposed a
secondary term coupled to epileptogenesis they term “epileptic maturation” to
describe the all encompassing processes that happen after epileptogenesis and
that influence the secondary changes in the clinical phenotype. Thus, Sloviter &
Bumanglag (2012) use these two terms to discuss different processes in the
development of epilepsy.
While the specificity of the definition given by Sloviter & Bumanglag (2012)
is warranted and enticing, this thesis uses the process of the brain acquiring an
initial insult and secondarily undergoing a series of epileptic events until the first
observable seizure is observed as the working definition of epileptogenesis.
Kindling: A Model of Epileptogenesis
Kindling is a process whereby an electrode, implanted in a limbic structure
in the brain, delivers an electrical stimulus that causes progressive and
permanent intensification of epileptiform, after-discharge (AD) activity that results
in generalized seizures after the same repeated subconvulsive electrical
stimulation (Goddard et al., 1969). In other words, the same current strength and
duration cause the animal to have a ‘worse’ seizure than before; a decrease in
seizure threshold occurs (called kindling acquisition).
In rodents the progression of kindling has been well characterized
electrographically and behaviorally (Racine, 1972). These different stages mimic
human seizures, with Racine stages 1-2 simulating complex partial seizures and
stages 3-5 mimicking secondary generalized seizures (Racine, 1972). Once a
fully kindled state is achieved (defined as two consecutive Racine 5 seizures for
any data presented in this thesis) spontaneous seizures may occur for the rest of
the animal’s life especially if the animal receives repeated stimuli over
consecutive months (Coulter et al., 2002; Racine, 1972). Furthermore, because
it is easier to induce a seizure in a animal once it has reached a stage 5 seizure
(see above), it is hypothesized that a permanent neurobiological change has
taken place in the brain; what drives that change is currently unknown (McIntyre
& Gilby, 2006). Several investigators have used the kindling model to study the
neurobiological changes that the brain undergoes at different stages of
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epileptogenesis (see Stables et al., 2003). However, this model is not without
pitfalls.
Because electrical current is sent through the brain during kindling, some
investigators believe this model may be a bit extreme or different compared to
the ‘natural’ process of epileptogenesis that occurs in humans (Reisner, 2003).
Thus, some arguments against using the kindling model are concerned with face
validity (i.e. how well does kindling represent human epileptogenesis?). Another
failing of the kindling model is that not all animals have spontaneous seizures
when kindled; thus, researchers may be studying changes in the brain that are
not relevant to spontaneous seizures if they do not select out only those animals
that do spontaneously seize to perform their experiments on (Pitkänen &
Halonen, 1998). Another issue that has been raised is that the implantation of
the kindling electrode into the brain may be a major cause of kindling rather than
the electrical stimulation; thus, it calls into question what causal factor one is
attempting to model (i.e. epileptogenesis from traumatic insult vs. electrical insult)
(Löscher, 2002). However, it should be noted that introduction of kindling
electrodes seldom if ever lead to seizures and only a relatively narrowly defined
current frequency and duration will produce the kindled seizure state (Löscher,
2002). Regardless, one has to keep in mind that the ambiguity created from a
poorly defined model can make results difficult to interpret and translate (i.e.
does a medication that works for epilepsy caused by traumatic brain injury also
work for ‘idiopathic’ epilepsy?).
Despite these shortcomings, the similarity of kindled seizures to human
seizures, the chronic nature of seizures in kindling, and the fact that
pharmaceuticals that prevent kindling have been effective in the clinic suggests
that kindling is accurate at modeling the stages of epileptogenesis (Löscher,
2002).
Epileptogenesis: Glutamate Dynamics & The Hippocampus
Epileptogenesis is a complex process involving molecular, cellular, and
neural network changes that result in dysregulated synaptic activity (Bertram,
2007). A lot of these changes occur in the hippocampus and glutamate
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dysregulation may be a driving factor (Matveeva et al., 2011a; Matveeva et al.,
2011b; Frasca et al., 2011; Bertram, 2009; Platt, 2007; Dalby & Mody, 2001;
Najm et al., 2001).
Evidence from several researchers suggests that there is an increase in
glutamate excitatory transmission in the hippocampus of animals and humans
undergoing epileptogenesis (Matveeva et al., 2011a; Matveeva et al., 2011b;
Frasca et al., 2011; Bertram, 2009; Platt, 2007; Dalby & Mody, 2001; Najm et al.,
2001). Further evidence shows that glutamate release and receptor activation is
increased after kindling especially in the DG (Matveeva et al., 2011a; Dalby &
Mody, 2001). GLT-1-lacking mice are also seizure prone further supporting the
role for glutamate excitotoxicity in epileptogenesis (Watanabe et al., 1999).
There is also an increase in the pool of ready-release glutamate at the mossy
fiber-pyramidal cell synapse in the CA3 as well as in DG neurons suggesting an
alteration in release probability (van der Hel et al., 2009; Goussakov et al., 2000).
More glutamate synapses, likely through mossy fiber sprouting, may appear
during epileptogenesis as well which could cause increased levels of
extracellular glutamate and glutamate system dysregulation (van der Hel et al.,
2009).
The number of NMDA receptors present in neuronal cell membranes
appears to increase during epileptogenesis (Musshoff et al., 2000). The
increased presence of NMDA receptors in neuronal membranes suggests a role
for synaptic plasticity in epileptogenesis; particularly since MK-801, an NMDA
antagonist, has antiepileptic effects during kindling but has no effect on acute
seizures (Morris et al., 2000; Wasterlain et al., 2000). Finally, evidence suggests
that ifenprodil, a NR2B containing NMDA antagonist, reduces pyramidal neuron
loss in the hippocampus during epileptogenesis (Frasca et al., 2011). Taken
together, these data suggest that NMDA receptors have an early role in disease
formation but do not have much of a role in disease maintenance or seizure
activity per se (Dalby & Mody, 2001; Wasterlain et al., 2000). There is evidence
that GluR2-lacking AMPA receptors are increased during epileptogenesis
suggesting that there may be more Ca2+ influx into neurons which could cause
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excitotoxicity and cell death as well as synaptic changes due to alterations in
second messenger signaling (Higuchi et al., 2000; Prince et al., 2000). GluR6,7
containing kainate receptors may also be decreased due to excitotoxicity which
may progress epileptogenesis as well (Putkonen et al., 2011). Metabotropic
receptors may also have effects on epileptogenesis.
mGluRs may contribute to epileptogenesis; in a disease state group I
mGluRs may be epileptogenic in nature when bound by glutamate whereas
group II mGluRs promote antiepileptogenic effects when bound by glutamate
(Sayin & Rutecki, 2003; Meldrum et al., 1999). Other processes may work to
promote epileptogenesis such as a decrease in GABAergic interneurons (which
could cause an in increase in glutamate neurotransmission) and a decrease in
membrane expressed GABAB receptors (which could also cause an increase in
glutamate neurotransmission) (Najm et al., 2001).
Several morphological changes in the hippocampus occur during
epileptogenesis that are likely associated with glutamate dysregulation
(Magloczky et al., 2000). Hippocampal sclerosis, shrinkage, and reactive gliosis
have all been documented in epilepsy (Moore et al., 1999). Neuronal loss in hilar
mossy cells, interneurons, and pyramidal neurons of the CA3 and CA1 are also
observed in the granule cell layer (Magloczky et al., 2000; Proper et al., 2000).
Evidence also exists suggesting that new gap junctions may form between small
neuronal ensembles which may explain some of the synchronous firing in
neurons during seizures (Bragin et al., 1999).
Aberrant rewiring in pyramidal cells of the CA1 and, from the granule cell
layer to the CA3, also occurs (Magloczky et al., 2000; Proper et al., 2000).
GABAergic sprouting in the DG and CA1 may occur as well; however, the
pyramidal cell sprouting in the CA1 predominates and causes a feed-forward
excitatory loop (Esclapez et al., 1999; Morin et al., 1999). Mossy fiber sprouting
onto granule cells, interneuron dendrites in the supragranule layer, and to
granule cells in the hilus also occurs and is speculated to create recurrent
excitatory circuits (Ribak et al., 2000).
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Sprouting is often thought to occur due to the loss of normal neuronal
targets (Dalby & Mody, 2001). However, evidence suggests that sprouting may
not be a cause of epileptogenesis but may be a result of it; thus, this should be
taken in to consideration when interpreting these results (Gombos et al., 1999;
Longo & Mello, 1998).
A lot of the changes seen in epileptogenesis are model specific; for
example neuronal loss and synaptic restructuring are more prevalent in status
epilepticus models as opposed to kindling models (Tuunanen & Pitkänen, 2000).
Thus, differences between models should be taken in to account when
attempting to uncover the changes that are universal to the process of
epileptogenesis. Other limbic structures may also be damaged and contribute to
epileptogenesis (see Bertram, 2009); however, only hippocampal data are
presented here as it is the focus of this thesis.

Thesis Outline

This thesis is concerned with the effect neuronal presynaptic proteins may
have on glutamate release and what affect that may have on the hippocampal
trisynaptic circuit and the process of epileptogenesis. Chapter two discusses the
materials, methods, instrumentation, methodology, and statistical analyses used
in this thesis. Chapter three discusses the use of enzyme-based microelectrode
arrays (MEAs) to measure glutamate in the DG, CA3, and CA1 in mice lacking a
negative regulator of glutamate release, tomosyn. Glutamate was measured in
hippocampal subregions in Tom+/+, Tom+/-, and Tom-/- mice. The most robust
finding was in the DG where an increase in spontaneous glutamate release, KClevoked glutamate peak amplitude, and KCl-evoked glutamate release were seen
as tomosyn protein expression was decreased across genotype. Thus, as
tomosyn expression decreases in the DG glutamate release increases; this may
be why tomosyn mice have a kindling phenotype.
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Figure 1.1 The Role of Tomosyn in Vesicle Priming
A. When tomosyn is not present, the vesicle membrane SNARE protein
VAMP2/synaptobrevin can combine with the plasma membrane SNAREs,
SNAP-25 and syntaxin, to create the 7S SNARE Complex and to prime the
vesicle for release into the synapse. B. When tomosyn is present, it
sequesters syntaxin and thus VAMP2/synaptobrevin, SNAP-25, and syntaxin
cannot combine to form a primed vesicle for release into the synapse. Figure
was adapted from Ashery et al. (2009).
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Figure 1.2 Current & Number of Stimulations Needed to Kindle/Genotype
A. The current needed to fully kindle Tom+/+ (n =7), Tom+/- (n = 7), and Tom-/(n = 14) animals was not significantly different between genotypes (one-way
ANOVA; F(2,25) = 0.37, p = 0.70). B. Significantly fewer stimulations were
required to kindle Tom-/- (n = 14) mice compared to Tom+/+ (n = 7) mice (oneway ANOVA; F(2,25) = 4.4, p = 0.024; Student’s t-test post-hoc, p = 0.012).

*Data courtesy of Dr. John T. Slevin, Dr. Sidney W. Whiteheart, and Ramona
Alcala
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Figure 1.3 Glutamate Synthesis & Storage
Neurons take up glutamine in a Na+ dependent fashion. Glutaminase then
synthesizes glutamate from glutamine. Glutamate is then packaged in
synaptic vesicles. Once glutamate is released it is taken up by astrocytes in a
Na+ dependent manner and converted to glutamine via glutamine synthase.
Glutamine is then shuttled back to neurons and resynthesized to glutamate.
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Figure 1.4 Typical Glutamate Synapse
Once glutamate is release into the synapse, it is free to bind to pre and postsynaptic receptors or to be removed by high affinity transporters on glial cells.
Glutamate will cause cellular excitation when bound to NMDA, AMPA, Kainate
or mGluR1,5 receptors. Glutamate will cause cellular inhibition when bound to
mGluR2,3,4,7,8 receptors. Glutamate binding to inhibitory presynaptic
mGluRs is an important negative feedback system for glutamate
release/regulation.
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Figure 1.5 The Trisynaptic Loop
The trisynaptic loop is the unidirectional flow of glutamatergic
neurotransmission in the hippocampus. The loop starts with the perforant path
beginning in the entorhinal cortex (EC) and synapsing on the granule cells of
the dentate gyrus (DG). Mossy axons then travel from the DG to synapse on
the pyramidal cells in CA3. Signals are then sent through neurons of the
bilateral Schaffer collaterals to synapse on pyramidal cells of the CA1 region
of both hippocampi. The signals are then transmitted from the CA1 to the
subiculum. From the subiculum signals return to the EC to complete the loop.
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Chapter Two: Materials & Methods

Animals

Tomosyn Mice
Tomosyn mice were provided by Dr. Sidney Whiteheart (University of
Kentucky). Experiments were performed on adult (20-37 g) Tom+/+ (n = 8),
Tom+/- (n = 8), and Tom-/- (n = 9) mice 10-12 weeks of age. The genotype of
animals used was determined by PCR analysis using DNA from tail clip biopsies.
All mice were bred, maintained, and used according to the University of Kentucky
IACUC approved protocol. Animals were housed in a 12-hour alternating
light/dark cycle with food and water available ad libitum. All electrochemical
glutamate recordings were performed during the light phase on average between
11:00 am-6:00 pm.

Principles of Electrochemistry

All glutamate recordings were performed using microelectrode arrays
(MEA) selective for glutamate. The measuring sites of the MEAs are fabricated
from inert platinum metal that can oxidize or reduced molecules of interest when
a potential is applied versus an Ag/AgCl reference electrode. A custom built
potentiostat and custom made software allowed for multiple, simultaneous
measurements from different recording sites on a single MEA. Amperometry
recordings were performed by applying a constant, fixed potential to the
reference electrode which allows molecules to be oxidized at the platinum
surfaces on the MEA (Gerhardt & Burmeister, 2000). The small currents
resulting from these molecular oxidations/reductions are then amplified thus
allowing the currents to be recorded. Amperometry allows the measurement of
Faradaic current (which is linear and directly proportional to the concentration of
molecules being oxidized/reduced) while minimizing non-Faradaic currents
(background signals) (Burmeister & Gerhardt, 2001). Thus, this technique allows
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for highly sensitive electrochemical measurements (micromolar) in the neuronal
extracellular space on a real-time, sub-second scale (millisecond) (Burmeister et
al., 2000).
Several neuromolecules such as dopamine (DA), norepinephrine (NE),
serotonin (5-HT), nitric oxide (NO) ascorbic acid (AA), 3,4-dihydroxyphenylacetic
acid (DOPAC), hydrogen peroxide (H2O2), and many others can be measured
because of their electroactive properties (Hascup et al., 2007; Burmeister et al.,
2000; Gerhardt & Burmeister, 2000 Gratton et al., 1989). Some molecules that
are not electroactive at a low enough potential such as lactate, glucose, and
glutamate can still be detected by the use of their respective oxidase enzymes by
generating the reporter molecule H2O2 (Hascup et al., 2007; Burmeister &
Gerhardt, 2001). Exclusion layers can also be plated (m-phenylenediamine
[mPD]; excludes by size) or baked (Nafion®; excludes by charge [negatively
charged thus repels anions]) on to the platinum surfaces of the MEA thus
shielding the MEA surface from molecules that can interfere with currents from
molecules of interest (Hascup et al., 2007).

Microelectrode Fabrication
The fabrication of these MEAs has been previously described (Hascup et
al., 2007; Burmeister et al., 2002; Burmeister et al., 2000). In this study W4-style
MEAs were used which have four platinum recording sites each measuring 20
μm x 150 μm in area. The four sites are arranged on the ceramic surface such
that one pair of sites is spaced 100 μm above the other pair with 30 μm between
the sites in a pair (Figure 2.1 A). This MEA configuration was selected for two
reasons: (1) the small size of the platinum sites allowed for discrete placement of
the recording sites in subregions of the hippocampus, (2) the design allowed for
two sites to be easily coated with glutamate oxidase (GluOx) for detection of
glutamate and for two sites to easily be coated with protein matrix to serve as the
sentinel sites (Hascup et al., 2007; Burmeister et al., 2000). For all calibrations
and anesthetized animal recordings an electrochemical measuring system
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(FAST-16mk III, Quanteon, LLC, Nicholasville, KY) was used to perform constant
voltage amperometry (+0.7 V vs. Ag/AgCl reference). Due to the ability of this
system to collect data from the MEA at a high rate (up to 1000 Hz) and due to the
small size of the MEA (microns) this technology allows for high spatial and
temporal resolution compared to other techniques such as microdialysis (Hascup
et al., 2007)

Microelectrode Preparation for Glutamate Recordings

All MEAs were made selective for glutamate as previously reported
(Hascup et al., 2007; Burmeister et al., 2002). Briefly, the pair of sites closest to
the tip of the electrode were coated with less than 1 μL of enzyme solution (1%
bovine serum albumin; 0.125% glutaraldehyde; 1 % GluOx) using a Hamilton
microsyringe (80100; Hamilton Co.). The pair of sites furthest from the tip of the
electrode were coated with less than 1 μL of BSA/glutaraldehyde solution that
was lacking the GluOx enzyme. Coating the electrode in this way allowed for
glutamate to be measured at the site pairs closest to the tip of the electrode while
only background signal/noise was measured at the sites furthest from the tip of
the electrode (known as the sentinel sites); tonic glutamate measurements can
then be obtained by subtracting the sentinel sites from the glutamate measuring
sites (see ‘Basal Glutamate Measurements’ for more details) (Figure 2.2).
After the MEAs were coated with GluOx, they were allowed to cure for at
least 48 hours. After curing, the MEAs were plated with mPD (5 mM; Acros
Organics, New Jersey, USA) for 20 minutes and then calibrated and used
immediately or within a timespan of 24 hours-2 weeks. The mPD is used to
create a size exclusion layer on the platinum recording sites of the MEA, making
the MEAs selective for glutamate, allowing only small molecules such as H2O2 to
pass while excluding larger molecules such as AA, DA, and DOPAC (Hascup et
al., 2007).
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In Vitro MEA Calibration

Although MEA fabrication and enzyme coating procedures are designed to
induce as little error as possible, inconsistencies in the platinum recording sites
and in the efficacy of the enzyme on the MEA surface exist. Thus, in order to get
an accurate measure of glutamate concentrations in the brain, each MEA is
calibrated with known concentrations of glutamate in order to ensure accurate in
vivo glutamate measurements.
The platinum recording sites of the MEA and a glass Ag/AgCl reference
electrode were submerged in 40 mL of phosphate-buffered saline (0.05 M PBS;
pH 7.4) encased in a water bath set at approximately 37°C. After the MEA
equilibrated to the PBS solution, 500 μL of 20 mM AA (termed the ‘interferent’)
was added to the PBS (beaker concentration = 250 μM) to check the adequacy
of the exclusion layer and to obtain a selectivity measurement of glutamate
versus AA for the MEA. Selectivity measures of 20:1 or higher are adequate and
are considered to block 95% of undesired molecules (see Hascup et al., 2007).
After the interferent was added, three serial 40 μL additions of 20 mM
glutamate (termed the ‘analyte’) were added to the PBS (beaker concentration =
20, 40, and 60 μM respectively) to generate a standard curve which equates
current from the oxidation of the reporter molecule, H2O2, to changes in known
analyte concentrations (Burmeister & Gerhardt, 2001). The slope for this
standard curve is calculated in nA/μM and the linearity of the line is calculated as
an R2; the slope is considered to be the sensitivity of the MEA for glutamate (see
Hascup et al., 2007). From the baseline measure and the slope the limit of
detection (LOD) is calculated as well; this is considered to be the lowest
concentration of glutamate the MEA can detect (the signal to noise ratio). For
W4 MEAs slopes of 3.0 pA/μM or higher, LODs of 1.0 μM or lower, and linarites
of R2 > 0.99 are considered adequate.
After the serial additions of glutamate a single 40 μL addition of 2 mM DA
was added to the PBS solution (beaker concentration = 2 μM) to test the
electrodes for their selectivity against DA. Lastly, a 40 μL addition of 8.8 mM
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H2O2 was added to the PBS (beaker concentration = 8.8 μM) to test the
responsiveness of all the platinum sites to peroxide (Figure 2.3).

In Vivo Glutamate Measurements

Basal Glutamate Measurements
Basal, tonic, or resting glutamate levels are caused by regulated release
and uptake of glutamate (Danbolt, 2001). This measurement is the most basic
measurement that can be obtained by the MEA. Data for this measure was
collected in all animals in this study.
As mentioned above, the W4 MEA has four sites: two coated with GluOx
to measure glutamate (measuring sites) and two coated with protein matrix that
cannot measure glutamate (sentinel sites). This method allows us to subtract the
background signal/noise caused by other electroactive substances and the
charging current of the MEA surface (measured on all sites) away from the
glutamate signal (measured only on the glutamate sensitive sites) thus leaving
an accurate basal glutamate concentration (Figure 2.4); this method is termed
self-referencing (Burmeister & Gerhardt, 2001; Day et al., 2006). By using this
method we can isolate the current created by the reporter molecule generated
from the enzymatic breakdown of glutamate. Basal glutamate measurements
were calculated in micromolar concentrations by taking the current (nA)
measured in the brain and dividing it by the MEA slope (nA/μM) obtained during
the calibration (Quintero et al., 2007).
Evoked Glutamate Measurements
KCl-evoked glutamate measures were obtained by locally applying 100 nL
of 70 mM KCl solution into distinct subregions of the hippocampus. KCl-evoked
glutamate release can be thought of as the maximum amount of glutamate
release possible from a subset of neurons per a given stimulation. Accurate KClevoked concentrations were obtained in μM concentrations through selfreferencing (Figure 2.4).
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Spontaneous Transient Glutamate Measurements
Because the MEA technology can record at a high sampling rate, rapid,
spontaneous glutamate transients can be detected in vivo as described in
Hascup et al. (2011a). These rapid events are usually small (below 1 μM in
concentration), fast (1 second or less) naturally occurring glutamate bursts that
are observed on the glutamate measuring sites but not on the sentinel sites
(Hascup et al., 2011). The self-referencing technique was used to accurately
measure glutamate transients in this study (Figure 2.5).

In Vivo Anesthetized Mice Recordings

In Vitro MEA Calibration Specifications
The W4 MEAs used in this study (n = 25) were calibrated according to the
methods described above and had the following average parameters (mean±
SD): slope (5.5 ± 2.1 pA/μM); LOD (0.75 ± 0.39 μM); selectivity (508 ± 1057); R2
(0.99). Note that these averages are roughly as good or better than published
observations (Hascup et al., 2011b).
Surgical Procedures
Male Tom+/+, Tom+/-, and Tom-/- mice were anesthetized using isoflurane
(vaporizer 1-3%; flow 1 L/min) and placed in a stereotaxic frame (David Kopf
Instruments, Tujunga, CA). A bilateral craniotomy was then performed by
removing a square area of bone approximately 3 mm x 3 mm in size between
bregma and lambda allowing access to the hippocampus. A small burr hole was
then drilled out over the frontal cortex and an Ag/AgCl reference electrode was
placed in the frontal cortex. The micropipette/MEA assembly was then attached
to the stereotaxic frame and moved accordingly to target the DG, CA3, and CA1
hippocampal subregions (Figure 2.1 B).
Stereotaxic coordinates were adapted from Paxinos and Franklin (2008).
Anterior-posterior and medial-lateral coordinates were taken from bregma, and
dorsal-ventral coordinates were taken from the surface of the brain. The
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following coordinates (in mm) were used: DG (AP: -2.3; ML: ±1.5; DV: -2.1); CA3
(AP: -2.3; ML: ±2.7; DV: -2.25); CA1 (AP: -2.3; ML: ±1.7: DV: -1.4).
Basal & Transient Glutamate Measurements
After the MEA equilibrated in the brain (approximately 20 minutes) basal
and transient glutamate measures were collected for approximately 40 minutes in
each brain area before any solutions were ejected. The order in which the
subregions were targeted was counter-balanced to control for any order effects.
Tonic and transient glutamate measures were collected in all animals. After 40
minutes of basal and transient glutamate measures, KCl was ejected into the
brain regions and evoked glutamate measures were collected.
KCl-Evoked Glutamate Measurements
A single-barrel glass micropipette (1mm o.d.; 0.58 i.d.; A-M Systems Inc.,
Everett, WA) was pulled to an inner diameter of 10 μm and was attached to the
MEA using Sticky Wax (Kerr Lab Corporation, Orange, CA) (Figure 2.1 C). The
pipette was positioned in the center of the four platinum sites 50 μm-100 μm from
the surface of the MEA (Figure 2.1 D; Figure 2.1 E). The pipette placement
allowed for the local application of 100 nL of 70 mM KCl (70 mM KCl, 79 mM
NaCl, 2.5 CaCl2; pH 7.4) in each subregion of the hippocampus to measure the
maximum evoked glutamate release.
A Picospritzer III (Parker Hannifin Corp. NJ, USA) was attached to the
micropipette via tubing and was used to precisely control the volume of KCl being
locally ejected into each brain region. A dissecting microscope fitted with a
calibrated reticule was used to measure the volume of KCl locally ejected into the
brain (Friedemann & Gerhardt, 1992). In each subregion of the hippocampus 610 Glutamate peaks were evoked by approximately 100 nL of KCl per ejection.
Evoked glutamate release was collected in all animals.
Confirmation of MEA Placement
At the end of every experiment, the micropipette waxed onto the MEA was
filled with green ink (Special Green Ink; KOH-I-NOOR Co.) and the MEA was
placed back into each of the hippocampal subregions where glutamate
recordings took place. Careful consideration was taken to make sure the MEA
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did not move on the stereotaxic frame while the pipette was being filled with ink.
While putting the electrode back into the brain areas after the recordings had
taken place was not ideal it was considered to be a good approximation of MEA
placement especially considering that there was no other method to mark
placement. Once the MEA was placed back into the brain the ink was ejected
(approximately 500-600 nL) into each of the brain regions then the animal was
euthanized and the brain was flash frozen using dry ice. Brains were cut into 40
μm thick slices using a cryostat and the slices were stained with Cresyl Violet
(Sigma-Aldrich). Slices were then visually analyzed using a microscope (Carl
Zeiss Co.) to confirm electrode placement in the DG, CA3, and CA1 (Figure 2.6).
There were no clear indications that a brain region was missed thus no data were
excluded due to incorrect electrode placement.
Data Analysis
Basal, transient, and KCl-evoked glutamate measures were recorded in
current (nA) and divided by the slope from the calibration (nA/μM) by the FAST
Analysis MATLAB® software (MathWorks, Natick, MA.) to acquire the
concentration of glutamate (μM) for each measure in each brain region (Quintero
et al., 2007). Data were collected and analyzed for all measures in Tom+/+ (n =
7), Tom+/- (n = 6), and Tom-/- (n = 9) mice.
Tonic glutamate measures were analyzed using self-referencing before
any KCl was ejected into the brain. Spontaneous transient measures were also
analyzed during the 40-minute baseline before any KCl was ejected into the
brain. Transient measures were analyzed by examining three specific
measurements: (1) amplitude of the transient peak; (2) the area under the
transient peak; (3) the number of transient peaks per a 10-minute bin.
KCl-evoked data was analyzed by examining the following specific
measurements: (1) the amplitude of the evoked peak; (2) the area under the
evoked peak (thought of as the total amount of glutamate released); (3) the time
to rise of the evoked peak (Trise) from baseline; (4) the first order rate of decay of
the evoked peak (k-1 [sec-1]; a measure of uptake) (Figure 2.4). The Fast
Analysis software exported all data to a spreadsheet to be analyzed.
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All data are presented as mean ± SEM and was statistically analyzed
using JMP®10 software (SAS Institute Inc., Cary, NC). One-way between subject
ANOVAs and linear trend analyses were conducted for all glutamate measures.
Outliers were excluded from analyses by using the Grubbs’ test. One outlier was
present for Tom+/+ animals, two outliers were present for Tom+/- animals, and no
outliers were present for Tom-/- animals. The Tukey HSD post-hoc test was used
to probe ANOVAs. Statistical significance was set at p < 0.05 for all statistical
tests.
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Figure 2.1 W4 MEA Setup
The W4 MEA is shown here to demonstrate the various ways it was used in this
thesis. A. Close up of the W4 MEA shows the configuration of the platinum
sites along with the measurements of the platinum sites (20 x 150 μm), the
distance the site pairs are from each other (100 μm), and the space between
one member of a pair from the other (30 μm). B. W4 MEA implanted into the
mouse hippocampus in the anesthetized setup. C. A micropipette waxed onto a
W4 MEA using putty and Sticky Wax. D. A micropipette positioned in the middle
of the four recording sites for local application of 70 mM KCl in the
hippocampus. E. A micropipette positioned approximately 70 μm above the W4
MEA for local application of KCl into the hippocampus.
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Figure 2.2 MEA Configuration for Self-Referenced Glutamate
Measurements
W4 image showing m-phenylenediamine (mPD) exclusion layer, bovine serum
albumin-glutaraldehyde protein matrix (BSA+Glut), and glutamate-oxidase
(GluOx) active enzyme layer. Green shaded sites: contain GluOx and thus
can create hydrogen peroxide (H2O2) from glutamate which can be oxidized by
the MEA (receiving two electrons [e-]). Blue shaded sites: sentinel sites that
contain protein matrix and thus can only measure background current and not
glutamate; the sentinel sites are subtracted from the glutamate recording sites
to acquire accurate basal glutamate levels in the brain (termed selfreferencing). mPD excludes ascorbic acid (AA) and other large molecules
(DA; DOPAC) by size thus stopping them from reaching the platinum
recording surfaces.
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Figure 2.3 Glutamate Calibration
After the electrode equilibrated in the PBS solution an addition of ascorbic acid
(AA; 250 μM) was added to the beaker to test the MEAs’ selectivity against
interferents. Three serial additions of glutamate (Glu) were then added to the
beaker (20, 40, 60 μM respectively) to generate a standard curve (dashed line;
R2 > 0.99) from which a slope (nA/μM) can be generated. The slope
represents the sensitivity of the MEA to glutamate and it can be used to
equate changes in current (nA) to changes in concentration (μM) in the brain.
Dopamine (DA; 2 μM) is added as a negative control. Hydrogen peroxide
(H2O2; 8.8 μM) is added as a positive control.
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Figure 2.4 Glutamate Measurements
The various glutamate measures analyzed in this thesis. Tonic Level: the
basal level of glutamate measured in the brain obtained by subtracting the
sentinel sites from the glutamate recording sites. Peak Amplitude: the
maximum amplitude of a KCl-evoked glutamate peak; an accurate
concentration in the brain is calculated by self-referencing. Trise: the time it
takes a KCl-evoked glutamate peak to reach its maximum height in seconds.
Peak Area: the area under a KCl-evoked glutamate peak in arbitrary units. k-1:
the glutamate uptake rate constant for a KCl-evoked peak in seconds-1; the
rate constant is calculated by fitting a first-order exponential curve to the
decaying position of the evoked peak.
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Figure 2.5 Spontaneous Glutamate Peak
An example of a naturally occurring spontaneous glutamate peak. Notice how
the peak was observed on the glutamate site but not on the sentinel site. This
is indicative of an actual glutamate peak as opposed to background current
which would be present on both sites. The subtracted site shows the actual
concentration (μM) of the spontaneous glutamate peak. Notice the small
amplitude (approximately 0.5 μM) and fast timespan (approximately 1 second)
of the spontaneous peak.
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Figure 2.6 Histological Placement of MEA
A representative histological slice (40 μm) of the mouse hippocampus showing
W4 MEA placement. Left Panel: green dye ejected via the micropipette waxed
onto the W4 MEA shows electrode placement in the CA3 and CA1. Right
Panel: green dye ejected via the micropipette waxed onto the W4 MEA shows
electrode placement in the DG. Scale bar = 500 μm.
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Chapter Three: Tomosyn Dysregulation Leads to Aberrant Glutamate
Release in the Dentate Gyrus of the Hippocampus in a Murine Model of
Epileptogenesis

Results

In this study we used electrochemical techniques with high spatial (μm)
and temporal (4 Hz) resolution to explore in vivo glutamate neurotransmission in
the DG, CA3, and CA1 subregions of the hippocampus in Tom+/+ (n = 7), Tom+/(n = 6), and Tom-/- (n = 9) animals. Histological analysis confirmed MEA
placements in the DG, CA3, and CA1 of all animals statistically analyzed. All
animals were analyzed using one-way ANOVAs and linear trends. All data are
presented as mean ± SEM.
Tonic Glutamate Measurements
A loss of tomosyn does not affect tonic glutamate levels in the trisynaptic
circuit. Tonic glutamate measurements were all approximately in the 1 to 3 μM
range and showed no statistical difference between genotype (DG: F(2,19) =
0.56, p = 0.58; CA3: F(2,19) = 0.70, p = 0.51; CA1: F(2,19) = 0.76, p = 0.48) or
within genotype (Tom+/+: F(2,18) = 0.11 , p = 0.90; Tom+/-: F(2,15) = 0.17 , p =
0.84; Tom-/: F(2,24) = 0.029, p = 0.97). No linear trends were present across
genotype in the trisynaptic loop (DG: t(19) = 0.75, p = 0.46; CA3: t(19) = 1.2, p =
0.25; CA1: t(19) = 1.2, p = 0.24) (Figure 3.1). For a summary of averages and pvalues see Table 3.1.
Spontaneous Peak Measures
Spontaneous glutamate recordings were collected during the 40 minute
period before KCl ejections; the parameters analyzed were the amplitude of
spontaneous peaks, the number of peaks per a 10-minute bin, and the area
under spontaneous peaks. Tomosyn loss does not affect the amplitude of
spontaneous glutamate peaks in the trisynaptic loop. The amplitude of the
spontaneous peaks were approximately between 0.1 and 0.5 μM and showed no
statistical difference between genotype (DG: F(2,19) = 0.062, p = 0.94; CA3:
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F(2,19) = 0.72, p = 0.50; CA1: F(2,19) = 1.3, p = 0.29) or within genotype
(Tom+/+: F(2,18) = 0.31, p = 0.74; Tom+/-: F(2,15) = 0.55, p = 0.59; Tom-/-: F(2,25)
= 0.19, p = 0.83.). No linear trend was present across genotype (DG: t(19) =
0.22, p = 0.83; CA3: t(19) = 1.1, p = 0.27; CA1: t(19) = 1.2, p = 0.23) (Figure 3.2).
See Table 3.2 for a summary of averages and p-values.
A roughly 50% knockdown of tomosyn appears to dysregulate glutamate
bursting patterns between the CA3 and CA1 in Tom+/- animals. The number of
peaks per a 10-minute bin were approximately between 5 and 15 peaks with no
statistical difference or linear trend in the hippocampus among genotype but with
a statistical difference between the CA3 and CA1 in Tom +/- animals (15 ± 2.6 vs.
5.4 ± 1.8, F(2,19) = 5.0, p = 0.022, Tukey post-hoc, p = 0.029) (Figure 3.3). For
a summary of averages and p-values see Table 3.3.
Tomosyn loss causes more glutamate to be spontaneously released in a
given release event as measured by the area under the glutamate peaks. The
area under spontaneous peaks was approximately between 0.1 and 0.5 abu with
no statistical difference between or within genotype in any of the brain regions;
however, there was a linear trend in the DG across genotype (Tom+/+: 0.13 ±
0.10 abu; Tom+/-: 0.19 ± 0.11 abu; Tom-/-: 0.33 ± 0.091 abu, t(19) = 2.2, p =
0.040) (Figure 3.4). See Table 3.4 for a summary of averages and p-values.
KCl-Evoked Glutamate Release
Tomosyn loss causes a higher concentration of maximum glutamate
release during a given evoked event. The KCl-evoked peak amplitudes were
approximately between 1 and 5 μM with a statistical difference in the DG
between Tom+/+ and Tom-/- mice along with a linear trend across genotype in the
DG (Tom+/+: 1.7 ± 0.78 μM; Tom+/-: 2.3 ± 0.84 μM; Tom-/-: 4.2 ± 0.69 μM, F(2,19)
= 4.0, p = 0.034, Tukey post-hoc, p = 0.029; t(19) = 2.8, p = 0.011) (Figure 3.5).
For a summary of averages and p-values see Table 3.5.
The amount of evoked glutamate released increases as tomosyn
expression is decreased across genotype as measured by the area under
evoked peaks. The area under KCl-evoked peaks was approximately between 5
and 26 abu with no statistical difference between or within genotype in any of the
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brain regions in the hippocampus; however, there was a linear trend in the DG
with an increase in total glutamate released as tomosyn was decreased across
genotype (Tom+/+: 8.1 ± 3.7 μM; Tom+/-: 11 ± 4.0 μM; Tom-/-: 19 ± 3.3, t(19) = 2.0,
p = 0.033) (Figure 3.6). See Table 3.6 for a summary of averages and p-values.
A loss in tomosyn expression does not affect the time it takes for an
evoked event to reach its maximum concentration; thus, tomosyn must not
regulate the speed of glutamate release. The time to rise of KCl-evoked peaks
was approximately between 2 and 3 seconds with no significant difference
between genotype (DG: F(2,19) = 0.27 , p = 0.77; CA3: F(2,19) = 0.048, p =
0.95; CA1: F(2,19) = 0.41 , p = 0.67) or within genotype (Tom+/+: F(2,18) = 0.52 ,
p = 0.60; Tom+/-: F(2,15) = 0.12 , p = 0.89; Tom-/-: F(2,24) = 0.22 , p = 0.81). No
linear trend was present across genotype in the trisynaptic loop (DG: t(19) =
0.72, p = 0.48 ; CA3: t(19) = 0.070, p = 0.95; CA1: t(19) = -0.78, p = 0.45) (Figure
3.7). See Table 3.7 for a summary of averages and p-values.
Tomosyn expression does not change the rate of decay of evoked
glutamate peaks; thus, tomosyn has no effect on glutamate transport. The k-1
rate of decay of KCl-evoked peaks was approximately between 0.4 and 2
seconds-1 with no significant differences between genotype (DG: F(2,19) = 0.63 ,
p = 0.54 ; CA3: F(2,19) = 0.81 , p = 0.46; CA1: F(2,19) = 0.049 , p = 0.95) or
within genotype (Tom+/+: F(2,18) = 0.43 , p = 0.66 ; Tom+/-: F(2,15) = 0.67 , p =
0.52; Tom-/-: F(2,24) = 0.22 , p = 0.81). No linear trend was present across
genotype in any of the brain regions (DG: t(19) = -1.1, p = 0.28; CA3: t(19) = 0.92, p = 0.37; CA1: t(19) = 0.30 , p = 0.77) (Figure 3.8). For a summary of
averages and p-values see Table 3.8.

Discussion

In this study basal glutamate levels, the peak amplitude of spontaneous
glutamate peaks, and the Trise and k-1 of KCl-evoked glutamate peaks showed no
significant difference or linear trend across or within Tom+/+, Tom+/-, or Tom-/mice. However, we observed a significant increase in the maximum
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concentration of evoked peaks in Tom-/- mice compared to Tom+/+ mice in the
DG. We also observed significant differences between the number of
spontaneous peaks per 10-minute bin between the CA3 and CA1 in Tom+/- mice
with the CA3 showing significantly more peaks than the CA1. Furthermore,
positive linear trends in the DG for the area under spontaneous glutamate peaks,
the amplitude of KCl-evoked peaks, and the area under KCl-evoked glutamate
peaks were also detected (suggesting that as tomosyn expression was
decreased across genotype more glutamate was released and a higher
concentration was present in the synapse). Taken together these results
suggest that a reduction in tomosyn expression leads to an increase in glutamate
release, especially in the DG.
Tomosyn Does Not Alter Tonic Glutamate Levels
We observed no statistical difference or linear trend in tonic glutamate
measurements in the hippocampus. This is consistent with what has been found
using MEA technology to measure glutamate in kindled rats and in the VAMP2+/genetic mouse model (Matveeva et al., 2011a; Matveeva et al., 2011b).
However, these findings are inconsistent with those using other techniques such
as microdialysis in different epileptogenic models.
Using microdialysis, Ueda et al. (2001) found an increase in basal
glutamate levels in the ventral hippocampus in a kainic acid model of
epileptogenesis. The differences between these results and our study may be
reconciled by the fact that MEAs have higher spatial (μm vs. mm) and temporal
(ms vs min.) resolution thus what may look like basal changes over minutes may
not actually be so when one looks at the changes on a timescale that is more
accurate to neurotransmitter release; for example we had an increase in the
amount of glutamate released in a given spontaneous peak. Microdialysis does
not collect data fast enough to detect these spontaneous peaks. Thus, what may
look like an increase in tonic glutamate levels using microdialysis may actually be
an increase in the amount of glutamate released per a spontaneous peak. It is
also possible that the changes seen in basal levels are model specific (Tuunanen
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& Pitkänen, 2000), thus explaining why they are seen in the kainic acid model but
not in the tomosyn genetic model or the kindling model.
Furthermore, evidence suggests that certain anesthesia’s can have effects
on resting glutamate levels (Rutherford et al., 2007). Considering Ueda et al.
(2001) used sodium pentobarbital as an anesthetic and we used isoflurane it is
possible that differences in basal levels were due to differences in the anesthetic
used. Nevertheless, more work in unanesthetized freely moving mice in different
models of epileptogenesis are needed to know for certain what effects, if any,
different anesthetics may have on basal glutamate levels.
Tomosyn Does Alter Spontaneous Glutamate Release
No significant difference or linear trend was found in the amplitude of
spontaneous peaks in the trisynaptic loop. This is a similar result to that
presented in Matveeva et al. (2011a) where no significant difference was seen in
the amplitude of spontaneous peaks in kindled rats compared to control rats in
the hippocampus contralateral to where the kindling electrode was placed.
However, that same study did find a significant difference in spontaneous
amplitude measurements in the DG and CA3 between kindled and control
animals ipsilateral to where the kindling electrode was placed. Thus, it is
possible that spontaneous amplitude changes only exist in the hemisphere of the
brain where the kindling stimulus occurs and that these changes are dependent
more on kindling than tomosyn protein expression.
We found a significant difference in the number of peaks per 10-minute
bin in Tom+/- mice between the CA3 and CA1. In contrast, Matveeva et al.
(2011a) found a difference in peaks per 5-minute bin between the DG and CA1 in
the hippocampal hemisphere ipsilateral to where the kindling electrode was
placed in kindled rats. However, no difference between the hippocampal
hemisphere contralateral to the stimulating electrode in kindled rats or in either
hemisphere of sham control rats was seen. Considering that our tomosyn mice
resemble non-kindled controls, it is possible that a roughly 50% reduction in
tomosyn is the reason for the difference in peaks per 10-minute bin. Further, it is
also possible that if we were to analyze our data using 5-minute bins as opposed
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to 10-minute bins these data may look similar; however, we chose to use 10minute bins because we collected spontaneous data for a longer time period than
Matveeva et al. (2011a) thus we did not think we needed to increase our peak
per bin resolution further by using 5-minute bins.
A more interesting question is why Tom+/- mice show dysregulation in this
measure and Tom-/- mice do not. This difference may be because several
different proteins also regulate glutamate release (Matveeva et al., 2007). Thus,
in Tom+/- mice where there is roughly a 50% reduction in tomosyn, the
compensatory response from other proteins may not be as robust as it is in
Tom-/- mice because some tomosyn is still present in heterozygous animals.
Further, it is unlikely that these differences are due to differential expression of
tomosyn in these brain regions (Barak et al., 2010) because the difference in 10miute bins between the CA3 and CA1 is not seen in the wild-type tomosyn mice.
Thus, some kind of compensatory response that occurred in Tom-/- mice but not
in Tom+/- mice is likely the reason for the dysregulation seen in the
heterozygotes.
A positive linear trend in the DG as tomosyn was decreased across
genotype for the area measured under spontaneous peaks was also observed.
The area under spontaneous peaks can be thought of as the total amount of
glutamate released (Matveeva et al., 2011b). Thus, decreasing tomosyn
expression increases the total amount of glutamate released by neurons in the
DG while not changing the peak amplitude. It is possible that a compensatory
response to a loss in tomosyn is greater in the CA3 and CA1 than in the DG
explaining why an effect is seen in the DG but not the CA3 or CA1.
Nevertheless, more experimentation is needed to explain why this difference may
exist.
Tomosyn Alters KCl-Evoked Glutamate Release
A significant difference between Tom+/+ and Tom-/- mice as well as a
positive linear trend as tomosyn expression was decreased across genotype in
KCl-evoked glutamate release in the DG was observed. Note that this finding is
not isolated to our methodology or model as other groups have found similar
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results using microdialysis in the hippocampus of rats with kainic acid and
cocaine-kindled induced epileptogenesis (Kaminski et al., 2011; Ueda et al.,
2001). Further, using MEAs to measure glutamate in the hippocampus of
VAMP2+/- mice with a kindling resistant phenotype, Matveeva et al. (2011b) found
a decrease in the amplitude of KCl-evoked glutamate peaks in the DG and CA3.
Considering that the tomosyn kindling phenotype is opposite the VAMP2+/model, it is not surprising to see an increase in the amplitude of KCl-evoked
glutamate peaks at least in the DG. Considering that changes in the
hippocampal glutamate system occur during kindling (see Matveeva et al.,
2011a) differences are likely seen in this measure simply because the KCl
ejections challenge an already vulnerable system.
We also observed a positive linear trend in the total amount of glutamate
released (as measured by the area under evoked peaks) in the DG as tomosyn
expression was decreased across genotype. In VAMP2+/- mice a decrease in
evoked area was seen in the CA3; it not surprising that the reverse is seen in
tomosyn mice, albeit the effect is seen in the DG instead of the CA3 (Matveeva
et al., 2011). We did not observe changes in the time to rise or k-1 decay rate of
the KCl-evoked peaks. Thus, it seems that the increase in peak area is due to
an increase in quantal glutamate release and not a difference in the time needed
to reach maximum release amplitude or in uptake.
These changes in phasic glutamate release may be seen exclusively in
the DG rather than CA3 and CA1 due to the role of the DG as ‘the gatekeeper’ of
the trisynaptic loop (Tamminga et al., 2012). Thus, it is possible that while
dysregulation happens in the DG, other compensatory responses may take place
further downstream in the CA3 and CA1 that attenuate this glutamate
dysregulation; a similar trend has been seen in the trisynaptic circuit with the
amplitude of spontaneous glutamate peaks in kindled rats (Matveeva et al.,
2011a). However, more experiments will need to be conducted to know exactly
what those differential compensatory responses may be.
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Conclusions

This study suggests that tomosyn has a role as a negative regulator of
glutamate release, particularly in the DG of the hippocampus. Taken together
with the fact that tomosyn knockout animals show a kindling phenotype, it
suggests that a dysfunction in this protein may promote the formation and
propagation of epilepsy. In addition to the differences found, it is possible that
other differences may exist that could be elucidated by changing some of the
experimental procedures.
It is possible that because our animals were tomosyn deficient from birth
compensatory responses occurred, at least in the CA3 and CA1, causing no
effects in these brain regions in the knockout mice. Thus, perhaps conditionally
knocking out tomosyn expression in adult mice may make it easier to elucidate
the range of effects this protein can have on glutamate neurotransmission. This
ideas could be incorporated into future experiments to potentially improve our
studies.
In the future, we plan to measure glutamate in kindled tomosyn animals to
assess what glutamatergic changes may have occurred in these animals after
kindling. We also plan to use the anti-seizure medication levetiracetam, which
may affect various presynaptic proteins associated with glutamate release, in
tomosyn and other genetic mice models in attempt to reverse the kindling
phenotype completely or at the least attenuate the kindling process. We would
also like to perform experiments on adult mice whose proteins are conditionally
knocked out (allowing us to perhaps see a broader range of possible effects
these proteins may have on the glutamate system). In these ways, we would be
able to further elucidate the mechanisms of epileptogenesis and to explore
potential ways to attenuate or eradicate the process.
In the United States alone, epilepsy affects millions of adults and
thousands of children every year. To date there is no cure for epilepsy and the
current treatments have varying degrees of efficacy. The processes the brain
undergoes to develop epilepsy are unknown. However, by studying
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epileptogenesis, it is possible that we may uncover these mechanisms and find
treatments to abort the process. To this end, this thesis provides electrochemical
data of aberrant hippocampal glutamate activity in an epileptic mouse phenotype
that may provide clues from which we and others can design further experiments
to answer the question "whereby epileptogenesis?".
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Table 3.1 Tonic Glutamate in Tomosyn Mice (μM)

Brain Region

Tom+/+

Tom+/-

Tom-/-

One-way
ANOVA

Linear
Trend

DG

1.8 ± 0.43

1.7 ± 0.47

2.2 ± 0.38

p = 0.58

p = 0.46

CA3

1.5 ± 0.40

1.8 ± 0.43

2.4 ± 0.35

p = 0.51

p = 0.25

CA1

1.5 ± 0.62

2.0 ± 0.67

2.6 ± 0.55

p = 0.48

p = 0.24

One-way
ANOVA

p = 0.90

p = 0.84

p = 0.97

All data presented as mean ± SEM
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Table 3.2 Amplitude of Spontaneous Glutamate Peaks in Tomosyn Mice
(μM)

Brain Region

Tom+/+

Tom+/-

Tom-/-

One-way
ANOVA

Linear
Trend

DG

0.23 ± 0.065

0.26 ± 0.070

0.26 ± 0.058

p = 0.94

p = 0.83

CA3

0.19 ± 0.066

0.26 ± 0.072

0.31 ± 0.058

p = 0.50

p = 0.27

CA1

0.24 ± 0.18

0.49 ± 0.20

0.47 ± 0.16

p = 0.29

p = 0.23

One-way
ANOVA

p = 0.74

p = 0.59

p = 0.83

All data presented as mean ± SEM
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Table 3.3 Spontaneous Glutamate Peaks/10-Minute bin in Tomosyn Mice

Brain Region

Tom+/+

Tom+/-

Tom-/-

One-way
ANOVA

Linear
Trend

DG

12 ± 2.1

13 ± 2.3

9.8 ± 1.8

p = 0.51

p = 0.44

CA3

12 ± 2.4

15 ± 2.6

14 ± 2.1

p = 0.78

p = 0.58

CA1

9.9 ± 1.7

5.4 ± 1.8

8.2 ± 1.5

p = 0.20

p = 0.60

One-way
ANOVA

p = 0.70

*p = 0.022

p = 0.066

All data presented as mean ± SEM
*Significance
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Table 3.4 Area Under Spontaneous Glutamate Peaks in Tomosyn Mice
(abu)

Brain Region

Tom+/+

Tom+/-

Tom-/-

One-way
ANOVA

Linear
Trend

DG

0.13 ± 0.10

0.19 ± 0.11

0.33 ± 0.091

p = 0.11

*p = 0.040

CA3

0.42 ± 0.18

0.18 ± 0.19

0.21 ± 0.15

p = 0.87

p = 0.84

CA1

0.30 ± 0.19

0.43 ± 0.20

0.39 ± 0.17

p = 0.35

p = 0.46

One-way
ANOVA

p = 0.59

p = 0.16

p = 0.90

All data presented as mean ± SEM
*Linear Trend

52

Table 3.5 Amplitude of KCl-Evoked Peaks in Tomosyn Mice (μM)

Brain Region

Tom+/+

Tom+/-

Tom-/-

One-way
ANOVA

Linear
Trend

DG

1.7 ± 0.78

2.3 ± 0.84

4.2 ± 0.69

*p = 0.034

*p = 0.011

CA3

2.1 ± 0.42

2.8 ± 0.45

2.3 ± 0.37

p = 0.40

p = 0.75

CA1

3.4 ± 1.1

3.6 ± 1.2

2.5 ± 0.97

p = 0.81

p = 0.83

One-way
ANOVA

p = 0.75

p = 0.79

p = 0.18

All data presented as mean ± SEM
*Significance & Linear
Trend
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Table 3.6 Area Under KCl-Evoked Peaks in Tomosyn Mice (abu)

Brain Region

Tom+/+

Tom+/-

Tom-/-

One-way
ANOVA

Linear
Trend

DG

8.1 ± 3.7

11 ± 4.0

19 ± 3.3

p = 0.095

*p = 0.033

CA3

5.8 ± 2.8

9.8 ± 3.0

11 ± 2.5

p = 0.25

p = 0.21

CA1

26 ± 7.5

9.4 ± 8.1

8.4 ± 6.6

p = 0.55

p = 0.28

One-way
ANOVA

p = 0.26

p = 0.78

p = 0.095

All data presented as mean ± SEM
*Linear Trend
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Table 3.7 Time to Rise of KCl-Evoked Peaks in Tomosyn Mice (sec)

Brain Region

Tom+/+

Tom+/-

Tom-/-

One-way
ANOVA

Linear
Trend

DG

2.2 ± 0.61

2.5 ± 0.66

2.9 ± 0.54

p = 0.77

p = 0.48

CA3

2.6 ± 0.63

2.4 ± 0.69

2.9 ± 0.56

p = 0.95

p = 0.95

CA1

2.7 ± 0.51

2.3 ± 0.55

2.4 ± 0.45

p = 0.67

p = 0.45

One-way
ANOVA

p = 0.60

p = 0.89

p = 0.81

All data presented as mean ± SEM
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Table 3.8 Decay Rate of KCl-Evoked Peaks in Tomosyn Mice (sec-1)

One-way
ANOVA

Linear
Trend

0.86 ± 0.67 0.44 ± 0.55

p = 0.54

p = 0.28

1.2 ± 0.46

0.89 ± 0.38

p = 0.46

p = 0.37

0.58 ± 0.27 0.59 ± 0.30 0.79 ± 0.24

p = 0.95

p = 0.77

Brain Region

Tom+/+

DG

1.7 ± 0.62

CA3

0.89 ± 0.43

CA1
One-way
ANOVA

p = 0.66

Tom+/-

p = 0.52

All data presented as mean ± SEM
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Tom-/-

p = 0.81

Figure 3.1 Tonic Glutamate is Not Different in Tomosyn-/- Mice

No significant difference was observed in tonic glutamate levels among or
within genotype. There was no linear trend in tonic glutamate levels across
genotype. These data suggest that a loss of tomosyn does not affect
glutamate levels in the trisynaptic circuit.
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Figure 3.2 Amplitude of Spontaneous Glutamate Peaks is No Different in
Tomosyn-/- Mice

No significant differences were seen in the amplitude of spontaneous
glutamate peaks between or within genotype. No linear trend was seen in
tonic glutamate levels across genotype. Taken together, tomosyn does not
seem to affect the amplitude of spontaneous glutamate peaks in the trisynaptic
circuit.

58

Figure 3.3 The Number of Spontaneous Peaks/10-Minute bin is Different
Between the CA3 & CA1 in Tomosyn+/- Mice

No Significant difference or linear trend was seen between genotype in the
trisynaptic circuit. A significant difference was observed in Tom +/- animals
between the CA3 and CA1 suggesting that approximately a 50% knockdown
in tomosyn causes a dysregulation in glutamate burst firing patterns in the
CA3 and CA1. Specifically, this 50% decrease in tomosyn seemed to
increase the firing pattern in the CA3 and decrease it in the CA1.
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Figure 3.4 The Total Amount of Glutamate Released in Each
Spontaneous Peak is Increased as Tomosyn is Decreased Across
Genotype in the DG

No significant difference was observed in the trisynaptic circuit between
genotype in the total amount of glutamate released in a spontaneous peak.
A liner trend was observed in the DG across genotype for this measure
suggesting that as tomosyn decreases more glutamate is release in each
spontaneous peak in the DG.

60

Figure 3.5 Amplitude of KCl-Evoked Glutamate Peaks is Larger in
Tomosyn-/- Mice Compared to Tomosyn+/+ Mice in the DG
A significant difference between Tom+/+ and Tom-/- animals and a linear trend
across genotype was observed in the DG in the amplitude of KCl-evoked
glutamate peaks. Thus, a loss of tomosyn causes the maximum amplitude of
an evoked glutamate peak to be larger in a given evoked event compared to
wild-type mice. No statistical difference or linear trend was seen in the CA3 or
CA1.
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Figure 3.6 The Total Amount of Evoked Glutamate Release Increased as
Tomosyn Decreased Across Genotype in the DG

No difference was seen between or within genotype in the area under KClevoked peaks. A linear trend was observed in this measure in the DG
suggesting that as tomosyn decreases the total amount of glutamate released
in a given evoked event increases.
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3.7 KCl-Evoked Glutamate Release is Not Faster in Tomosyn-/- Mice

No significant difference was seen between or within genotype in the time to
rise of KCl-evoked glutamate peaks. No linear trend was seen in this measure
across genotype. This lack of difference suggests that a loss of tomosyn does
not affect how fast glutamate is released from neurons in the trisynaptic circuit.
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Figure 3.8 The Uptake of KCl-Evoked Glutamate Peaks is Not Faster in
Tomosyn-/- Mice

No significant difference was seen between or within genotype in the decay
rate of KCl-evoked glutamate peaks. No linear trend was observed in this
measure across genotype. Taken together these results suggest that a loss of
tomosyn does not affect the uptake rate of glutamate in the trisynaptic circuit.
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